Evidence map›Paper›PMID 19897736›Full record

ArticleEukaryotic cell2010

A chemical genetic screen for modulators of exocytic transport identifies inhibitors of a transport mechanism linked to GTR2 function.

Lisha Zhang, Min Huang, Edina Harsay

Open access · diamondAbstract read
In one paragraph

Article in Eukaryotic cell, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A high-throughput screen for chemical inhibitors of exocytic transport in yeast.Chembiochem : a European journal of chemical biology · 2010
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lisha ZhangDepartment of Molecular Biosciences, University of Kansas, Lawrence, KS 66045-2106, USA.
Min Huang
Edina Harsay
University of Kansas · US

Funding

WEIGHT CONTROL, CELL SIGNALING AND CANCER PREVENTIONP20RR015563 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI ZUFFEREY, RACHEL · 2000 to 2009
$20.1M
Pathway-Specific Inhibitors of Post-Golgi TransportR21NS061754 · NINDS · UNIVERSITY OF KANSAS LAWRENCE · PI HARSAY, EDINA · 2007 to 2007
$139k
Identify compounds that target post-Golgi secretion(RMI)R03NS050784 · NINDS · UNIVERSITY OF KANSAS LAWRENCE · PI HARSAY, EDINA · 2004 to 2004
$72k
NCRR NIH HHS P20 RR015563NCRR NIH HHS P20 RR15563NINDS NIH HHS R03 NS050784NINDS NIH HHS R21 NS061754
6 · The paper itself

Abstract

Membrane and protein traffic to the cell surface is mediated by partially redundant pathways that are difficult to perturb in ways that yield a strong phenotype. Such robustness is expected in a fine-tuned process, regulated by environmental cues, that is required for controlled cell surface growth and cell proliferation. Synthetic genetic interaction screens are especially valuable for investigating complex processes involving partially redundant pathways or mechanisms. In a previous study, we used a triple-synthetic-lethal yeast mutant screen to identify a novel component of the late exocytic transport machinery, Avl9. In a chemical-genetic version of the successful mutant screen, we have now identified small molecules that cause a rapid (within 15 min) accumulation of secretory cargo and abnormal Golgi compartment-like membranes at low concentration (<2 muM), indicating that the compounds likely target the exocytic transport machinery at the Golgi. We screened for genes that, when overexpressed, suppress the drug effects, and found that the Ras-like small GTPase, Gtr2, but not its homolog and binding partner, Gtr1, efficiently suppresses the toxic effects of the compounds. Furthermore, assays for suppression of the secretory defect caused by the compounds suggest that Gtr proteins can regulate a pathway that is perturbed by the compounds. Because avl9Delta and gtr mutants share some phenotypes, our results indicate that the small molecules identified by our chemical-genetic strategy are promising tools for understanding Avl9 function and the mechanisms that control late exocytic transport.

Indexed as

Drug Evaluation, PreclinicalHigh-Throughput Screening AssaysPharmaceutical PreparationsEndosomesExocytosisGolgi ApparatusMolecular StructureMonomeric GTP-Binding ProteinsSaccharomyces cerevisiaeSaccharomyces cerevisiae ProteinsSignal TransductionGTR2 protein, S cerevisiaeMonomeric GTP-Binding ProteinsPharmaceutical PreparationsSaccharomyces cerevisiae Proteins

Identifiers

PMID19897736
PMCPMC2805290
OpenAlexW2126827381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.